Molecular Imaging and Therapy for Neuroendocrine Tumors
- 109 Downloads
Neuroendocrine tumors (NETs) are relatively rare, with 12,000–15,000 new cases diagnosed annually in the USA. Although NETs are a diverse group of neoplasms, they share common molecular targets that can be exploited using nuclear medicine techniques for both imaging and therapy. NETs have traditionally been imaged with SPECT imaging using 111In-labeled octreotide analogs to detect neoplasms with somatostatin receptors. In addition, certain NETs (pheochromocytomas, paragangliomas, and neuroblastomas) are also effectively imaged using 123I- or 131I-labeled metaiodobenzylguanidine (MIBG), an analog of guanethidine. More recently, PET imaging with 68Ga-labeled somatostatin receptor (SSR) analogs allows neuroendocrine tumors to be imaged with much higher sensitivity. 68Ga-DOTATATE was approved as a PET tracer by the FDA in June 2016. In addition to imaging, both MIBG and DOTATATE can be labeled with therapeutic radionuclides to deliver targeted radiation selectively to macroscopic and microscopic tumor sites. The incorporation of the same molecular probe for imaging and therapy provides a radio-theranostic approach to identifying, targeting, and treating tumors. Over the years, several centers have experience treating NETs with high-dose 131I-MIBG. 177Lu-DOTATATE was approved by the FDA in 2018 for treatment of gastroenteropancreatic NETs and constitutes a major advancement in the treatment of these diseases. In this paper, we provide an overview of imaging and treating neuroendocrine tumors using MIBG and SSR probes. Although uncommon, neuroendocrine tumors have provided the largest experience for targeted radionuclide imaging and therapy (with the exception of radioiodine treatment for thyroid disease). In addition to benefitting patients with these rare tumors, the knowledge gained provides a blueprint for the development of future paired diagnostic/therapeutic probes for treating other diseases, such as prostate cancer.
KeywordsSomatostatin receptor PET/CT Peptide receptor radionuclide therapy (PRRT) DOTATATE MIBG Theranostic
Compliance with Ethical Standards
Conflict of Interest
The authors declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, et al. Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med. 2016;57:708–14. https://doi.org/10.2967/jnumed.115.163865.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Waldmann CM, Stuparu AD, Dam RMV, Slavik R. The search for an alternative to [68Ga]Ga-DOTA-TATE in neuroendocrine tumor theranostics: current state of 18F-labeled somatostatin analog development. Theranostics. 2019;9:1336–47. https://doi.org/10.7150/thno.31806.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134:315–29. https://doi.org/10.7326/0003-4819-134-4-200102200-00016.CrossRefPubMedGoogle Scholar
- 12.• Pryma DA, Chin BB, Noto RB, et al. Efficacy and safety of high-specific-activity I-131 MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2018. https://doi.org/10.2967/jnumed.118.217463 Study outlining the improved response rates of pheochromocytoma and paragangliomas to higher doses of 131I-MIBG.CrossRefGoogle Scholar
- 15.Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27:4162–8. https://doi.org/10.1200/JCO.2008.21.3496.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Kane A, Thorpe MP, Morse MA, Howard BA, Oldan JD, Zhu J, et al. Predictors of survival in 211 patients with stage IV pulmonary and Gastroenteropancreatic MIBG-positive neuroendocrine tumors treated with 131I-MIBG. J Nucl Med. 2018;59:1708–13. https://doi.org/10.2967/jnumed.117.202150.CrossRefPubMedGoogle Scholar
- 20.Ezziddin S, Sabet A, Logvinski T, Alkawaldeh K, Yong-Hing CJ, Ahmadzadehfar H, et al. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors. J Nucl Med. 2013;54:2032–8. https://doi.org/10.2967/jnumed.112.119313.CrossRefPubMedGoogle Scholar
- 25.Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to Iodine-131-Metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25:1054–60. https://doi.org/10.1200/JCO.2006.09.3484.CrossRefPubMedGoogle Scholar
- 26.Maqsood MH, Din ATU, Khan AH. Neuroendocrine tumor therapy with lutetium-177: a literature review. Cureus. 2019. https://doi.org/10.7759/cureus.3986.
- 27.Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, et al. Erratum to: the joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;41:584. https://doi.org/10.1007/s00259-013-2454-3.CrossRefPubMedCentralGoogle Scholar
- 28.Bergsma H, Lom KV, Raaijmakers MH, Konijnenberg M, Kam BBL, Teunissen JJ, et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2017;59:452–8. https://doi.org/10.2967/jnumed.117.189712.CrossRefPubMedGoogle Scholar
- 29.• Nastos K, Cheung VT, Toumpanakis C, Navalkissoor S, Quigley A-M, Caplin M, et al. Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. J Surg Oncol. 2017;115:425–34. https://doi.org/10.1002/jso.24553 Study comparing the effectiveness of 131I-MIBG and PRRT for pheochromocytomas and paragangliomas.CrossRefGoogle Scholar
- 30.Brabander T, Zwan WAVD, Teunissen JJ, Kam BL, Feelders RA, Herder WWD, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617–24. https://doi.org/10.1158/1078-0432.CCR-16-2743.CrossRefPubMedGoogle Scholar
- 31.•• Strosberg J, El-Haddad G, Wolin E, Hendifar A, Et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. The New England Journal of Medicine 2017:376:125–135. DOI: https://doi.org/10.1056/NEJMoa1607427. Large clinical trial demonstrating the effectiveness of 177Lu-DOTATATE for midgut neuroendocrine tumors.CrossRefGoogle Scholar